Lebrikizumab, a monoclonal antibody that inhibits an interleukin named IL-13, is especially promising in treatment of this disease. Having been in development by Almirall and Eli Lilly and Company ...

In 2024, Almirall’s collaborator Lilly received US FDA approval for lebrikizumab and subsequently launched the product in the US. Lebrikizumab is an anti-IL13 monoclonal antibody for the ...

Almirall is within sniffing distance of EU approval for its IL-13 inhibitor lebrikizumab for atopic dermatitis, setting up a challenge to Sanofi and Regeneron’s market-leading Dupixent.

It is anticipated that the atopic dermatitis market will mirror the trajectory seen in the psoriasis market in recent years, where Ilumetri® continues to show strong sustained growth supporting ...

BARCELONA, Spain, September 25, 2024--More than 80 percent of adults and adolescents with moderate-to-severe atopic dermatitis who responded to lebrikizumab treatment at Week 16 in the ADvocate 1 and ...

BARCELONA, Spain, September 25, 2024--More than 80 percent of adults and adolescents with moderate-to-severe atopic dermatitis who responded to lebrikizumab treatment at Week 16 in the ADvocate 1 and ...